KT-3283, a duel PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field VANCOUVER, BC & RIYADH, SA – Rakovina Therapeutics Inc. (“Rakovina” or… Read More
New $195 million facility will further enhance AbbVie’s active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in… Read More
New UBC study reveals benztropine’s potential to treat the world’s deadliest infectious disease and combat growing antibiotic resistance. A medication developed in the 1950s to treat Parkinson’s disease may offer… Read More
Coming Fall 2025 The International Society for Stem Cell Research (ISSCR) and STEMCELL Technologies are proud to announce a new partnership to produce a free, on-demand course for researchers seeking to incorporate… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer,… Read More
